2015
DOI: 10.1016/j.ejim.2015.04.008
|View full text |Cite
|
Sign up to set email alerts
|

New onset heart failure — Clinical characteristics and short-term mortality. A RICA (Spanish registry of acute heart failure) study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
9
1
3

Year Published

2016
2016
2023
2023

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 39 publications
(15 citation statements)
references
References 27 publications
2
9
1
3
Order By: Relevance
“…They had lower readmission (p<0.05). This fact is similar to other studies, for example, the RICA study in Spain whose three-month mortality rate was 5.2% versus 13% in the acute chronic [2]. Patients with HF "de novo" had a lower readmissions, similar to NOVICA study, in Spain, in 2019 [5].…”
Section: Dear Editorsupporting
confidence: 87%
See 1 more Smart Citation
“…They had lower readmission (p<0.05). This fact is similar to other studies, for example, the RICA study in Spain whose three-month mortality rate was 5.2% versus 13% in the acute chronic [2]. Patients with HF "de novo" had a lower readmissions, similar to NOVICA study, in Spain, in 2019 [5].…”
Section: Dear Editorsupporting
confidence: 87%
“…Acute HF is characterized by abrupt presentation of symptoms, with the need for urgent medical intervention. If the patient has no history or symptoms of HF, it can be said to have a "de novo" HF [2]. On the contrary if the patient already has a previous diagnosis of HF whose symptoms worsen acutely it is called "acute chronic" [2,3].…”
Section: Dear Editormentioning
confidence: 99%
“…This nationwide registry includes participants of both sexes, aged 50 and older, with HF according to the criteria of the European Society of Cardiology [15]. The RICA registry has been described in previous publications [16,17].…”
Section: Populationmentioning
confidence: 99%
“…As reported, ARB drugs gave limited end-points benefits to patients with myocardial infarction and cardiovascular disease, compared with placebo [ 28 , 29 ]. However, other investigations showed that ACEI/ARB and beta-blockers drugs can significantly reduce all-cause mortality and cardiovascular mortality [ 30 33 ]. Consistent with them, our results showed that in control group the proportion of patients who received ACEI/ARB drugs and beta-blockers was significantly higher than that in adverse group, further determining their protective roles in management of AHF patients.…”
Section: Discussionmentioning
confidence: 99%